ClinicalTrials.gg
DrugBiological

Certolizumab Pegol clinical trials

Also written CDP870 and Certolizumab.

studies test it
99
open now
8
in phase 3
58
first study started
2002

How each study uses Certolizumab Pegol is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the Certolizumab Pegol studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
22 Apr 2008 · CIMZIA · BLA 125160 (FDA, Drugs@FDA)
European Union
1 Oct 2009 · Cimzia · EMEA/H/C/001037 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Cimzia
70
Certolizumab Pegol
62
CZP
25
Certolizumab Pegol (CZP)
6
Certolizumab Pegol (CDP870)
6

Development codes

CDP870
36

Other names

Certolizumab
7

Studies by the year they started

99 studies that test it; most in 2010 (11)

Studies that test Certolizumab Pegol, by start year
YearStudies
20021
20033
20043
20056
20068
20077
20088
20097
201011
20117
20124
20134
20147
20158
20161
20174
20203
20212
20221
20231
20252
20261

By phase

A phase 1/2 study counts in both.

Phase 1
8
Phase 2
15
Phase 3
58
Phase 4
17
No phase
3

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 73 · Other 26

UCB Pharma (36) · UCB BIOSCIENCES GmbH (6) · UCB Pharma SA (6) · UCB Biopharma SRL (5) · UCB Biopharma S.P.R.L. (5) · Astellas Pharma Inc (4) · Memorial Sloan Kettering Cancer Center (2) · Korea Otsuka Pharmaceutical Co., Ltd. (2)

Often tested with

Tested in the same studies.

Adalimumab (9) · Methotrexate (7) · Infliximab (7) · Etanercept (6) · Abatacept (6) · Hydroxychloroquine (4) · Sulfasalazine (4) · Leflunomide (4)

Related medicines

As reviewed, each with the page that says it.

Studies

Open first, then newest update. How each study uses Certolizumab Pegol is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 99

See all 99 studies that test Certolizumab Pegol →

Given beside what is tested · 3 — Certolizumab Pegol is usual care or a partner of the new treatment
As the comparator · 1 — what is tested is compared with Certolizumab Pegol

Codes

What other systems call Certolizumab Pegol · ClinicalTrials.gg INT006523

  • MeSH (NLM) D000068582Certolizumab PegolConfirmed ClinicalTrials.gov, NLM, Wikidata
  • UNII (FDA) UMD07X179ECERTOLIZUMAB PEGOLConfirmed FDA, NLM
  • RxNorm 709271One source FDA
  • NCI Thesaurus C80972Certolizumab PegolOne source FDA

Also registered as certolizumab (UNII G6ADW90R16 · RxNorm 709271).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.